Lilliam Ribeiro

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

J. E. Brewer, B. Levine, M. Kalos, 2015, Nature Medicine.

Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.

K. Odunsi, C. Mackall, G. Kari, 2016 .